bempedoic acid (NEXLETOL) Report issue

Small molecule Approved FDA
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia.   Wikipedia

Chemistry

  • SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O
  • InChIKey: HYHMLYSLQUKXKP-UHFFFAOYSA-N
  • Mol. Mass: 344.49
  • ALogP: 4.47
  • ChEMBL Molecule:
    bempedoic acid  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$8.1827 - $10.5349
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( ezetimibe (zetia), bempedoic acid (NEXLETOL) )

Alternative names

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | bempedoic acid | esp55016 | etc-1002

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Hypercholesterolemia (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Atherosclerosis (Phase 3)

Cardiovascular Diseases (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hypertension (Phase 2)

Pharmacological and Toxicological Phenomena (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue